Injectable Small Molecules

Cell and gene therapies and biopharmaceuticals justifiably capture attention for their immense potential to transform human health. But did you know that in 2023, 62% of FDA-approved drugs were small molecules? In fact, 34 of the 55 new drug approvals fell into this category.

Whether you're manufacturing traditional small molecule therapeutics, vaccines, or GLP-1 derivatives, bioMérieux is your trusted partner in prioritizing product and patient safety.